<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1209245904
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACTOS 30MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIOGLITAZONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        87.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BG03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Actos contains pioglitazone. It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately. This is the diabetes that usually develops in adulthood.</p><p>Actos helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. Your doctor will check whether Actos is working 3 to 6 months after you start taking it.</p><p>Actos may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Actos</strong></p><ul><li>If you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in Section 6).</li><li>If you have heart failure or have had heart failure in the past.</li><li>If you have liver disease.</li><li>If you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, nausea or vomiting).</li><li>If you have or have ever had bladder cancer.</li><li>If you have blood in your urine that your doctor has not checked.</li></ul><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Actos (also see Section 4).</p><ul><li>If you retain water (fluid retention) or have heart failure problems, in particular if you are over 75 years old. If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor.</li><li>If you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).&bull; If you have cysts on your ovaries (polycystic ovary syndrome). There may be an increased possibility of becoming pregnant because you may ovulate again when you take Actos. If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy.</li><li>If you have a problem with your liver or heart. Before you start taking Actos you will have a blood sample taken to check your liver function. This check may be repeated at intervals. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Actos and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</li><li>If you take Actos with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).</li><li>You may also experience a reduction in blood count (anaemia).</li><li>Broken bones:&nbsp; A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.</li></ul><p><strong>Children and adolescents Other medicines and Actos</strong></p><p>Use in children and adolescents under 18 years is not recommended.</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>You can usually continue to take other medicines whilst you are being treated with Actos. However, certain medicines are especially likely to affect the amount of sugar in your blood:</p><ul><li>Gemfibrozil (used to lower cholesterol)</li><li>Rifampicin (used to treat tuberculosis and other infections)</li></ul><p>Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and your dose of Actos may need to be changed.</p><p><strong>Actos with food and drink Pregnancy and breast-feeding</strong></p><p>You may take your tablets with or without food. You should swallow the tablets with a glass of water.</p><p><em>Pregnancy category C</em></p><p>Tell your doctor if:</p><ul><li>You are, you think you might be or are planning to become pregnant.</li><li>You are breast-feeding or if you are planning to breast-feed your baby.</li></ul><p>Your doctor will advise you to discontinue this medicine.</p><p><strong>Driving and using machines</strong></p><p>This medicine will not affect your ability to drive or use machines but take care if you experience abnormal vision.</p><p><strong>Actos contains lactose </strong></p><p>Actos contains lactose. Each tablet of Actos 15 mg and 30 mg Tablets contains 92.539 mg or 76.340 mg lactose; respectively. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Actos.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily. Your doctor may increase the dose to a maximum of 45 mg once a day. Your doctor will tell you the dose to take.</p><p>If you have the impression that the effect of Actos is too weak, talk to your doctor. When Actos is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.</p><p>Your doctor will ask you to have blood tests periodically during treatment with Actos. This is to check that your liver is working normally.</p><p>If you are following a special diet for diabetes, you should continue with this while you are taking Actos.</p><p>Your weight should be checked at regular intervals; if your weight increases, inform your doctor.</p><p><strong>If you take more Actos than you should</strong></p><p>If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. Your blood sugar could fall below the normal level and can be increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.</p><p><strong>If you forget to take Actos</strong></p><p>Take Actos daily as prescribed. However, if you miss a dose, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Actos</strong></p><p>Actos should be used every day to work properly. If you stop using Actos, your blood sugar may go up. Talk to your doctor before stopping this treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>In particular, patients have experienced the following serious side effects: </em></strong></p><p>Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Actos in combination with insulin. Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you experience any of these, especially if you are over the age of 65, seek medical advice straight away.</p><p>Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Actos. Signs and symptoms include blood in your urine, pain when urinating or a sudden need to urinate. If you experience any of these, talk to your doctor as soon as possible.</p><p>Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking Actos in combination with insulin. If you experience this side effect, talk to your doctor as soon as possible.</p><p>Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Actos and have also been reported in male patients (frequency cannot be estimated from the available data) taking Actos. If you experience this side effect, talk to your doctor as soon as possible. Blurred vision due to swelling (or fluid) at the back of the eye (frequency cannot be estimated from the available data) has also been reported in patients taking Actos. If you experience this symptom for the first time, talk to your doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.</p><p>Allergic reactions have been reported (frequency cannot be estimated from the available data) in patients taking Actos. If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.</p><p><strong><em>The other side effects that have been experienced by some patients taking Actos are: </em></strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Respiratory infection</li><li>Abnormal vision</li><li>Weight gain</li><li>Numbness</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Inflammation of the sinuses (sinusitis)</li><li>Difficulty sleeping (insomnia)</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Increase in liver enzymes</li><li>Allergic reactions</li></ul><p><strong><em>The other side effects that have been experienced by some patients when Actos is taken with other antidiabetic medicines are: </em></strong></p><p><strong>Very common (may affect more than 1 in 10 people) Common (may affect up to 1 in 10 people)</strong></p><ul><li>Decreased blood sugar (hypoglycaemia)</li><li>Headache</li><li>Dizziness</li><li>Joint pain</li><li>Impotence</li><li>Back pain</li><li>Shortness of breath</li><li>Small reduction in red blood cell count</li><li>Flatulence</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Sugar in urine, proteins in urine</li><li>Increase in enzymes</li><li>Spinning sensation (vertigo)</li><li>Sweating</li><li>Tiredness</li><li>Increased appetite</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pioglitazone hydrochloride.</p><p>Each tablet of Actos 15 mg Tablets contains pioglitazone hydrochloride equivalent to 15 mg pioglitazone.</p><p>Each tablet of Actos 30 mg Tablets contains pioglitazone hydrochloride equivalent to 30 mg pioglitazone. The other ingredients are lactose, calcium carboxymethylcellulose, hydroxypropyl cellulose and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Actos 15 mg Tablets are white to off-white round convex tablets, debossed “15” on one side and “ACTOS” on the other in high density polyethylene plastic bottles sealed with plastic child resistant caps with silica gel desiccant.
Actos 30 mg Tablets are white to off-white round flat tablets, debossed with “30” on one side and “ACTOS” on the other in high density polyethylene plastic bottles sealed with plastic child resistant caps with silica gel desiccant. 
Pack size: 30 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC</p><p>P.O. Box 42</p><p>Sult, Jordan</p><p>Tel: + (962-5) 3492200</p><p>Fax: + (962-5) 3492203</p><p><strong>Under licensed from</strong></p><p>Takeda Pharmaceutical Company Limited</p><p>1-1 Doshomachi 4-Chome-ku</p><p>Osaka 540-8645, Japan</p><p>Tel: +81-6-6204-2111</p><p>Fax: +81-6-6-6204-2948</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.<br />&bull; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet  was  last revised in 10/2020; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي آكتوس على البيوغليتازون. وهو دواء مضاد للسكري يستخدم لعلاج مرض السكري من النوع الثاني (غير المعتمد على الأنسولين) لدى البالغين، عندما يكون الميتفورمين غير مناسب أو غير فعال. هذا النوع من السكري يتكون عادة&nbsp; خلال سن الرشد.</p><p dir="RTL">يساعد آكتوس على التحكم في مستوى سكر الدم عندما يكون لديك سكري من النوع الثاني وذلك من خلال مساعدة جسمك على الاستفادة من الانسولين الذي يفرزه جسدك. وسيقوم طبيبك بالتأكد من فعالية آكتوس بعد ٣&nbsp; إلى&nbsp;٦ أشهر بعد بدء تناولك له.</p><p dir="RTL">يمكن استخدام آكتوس كعلاج منفرد في المرضى الغير قادرين على تناول الميتفورمين، وعندما يكون العلاج بالحمية والتمارين قد فشل في التحكم بسكر الدم أو يمكن أن يضاف إلى علاجات أخرى (مثل الميتفورمين، سلفونيليوريا أو الأنسولين)&nbsp;والذي قد فشل في تقديم التحكم الكافي في سكر الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول آكتوس</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية للبيوغليتازون أو لأي من المواد المستخدمة في تركيبة&nbsp; هذا الدواء (المدرجة في القسم ٦).</li><li>إذا كنت تعاني أو عانيت سابقا<sup>ً</sup> من فشل القلب.</li><li>إذا كنت تعاني من أمراض الكبد.</li><li>إذا عانيت من الحماض الكيتوني السكري (إحدى مضاعفات السكري يسبب خسارة سريعة في الوزن، الغثيان أو التقيؤ).</li><li>إذا كنت مصابا<sup>ً</sup> أو أصبت سابقا<sup>ً</sup> بسرطان المثانة.</li><li>في حال وجود دم في البول لم يتم فحصه من قبل طبيبك.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول آكتوس (انظر ايضا<sup>ً</sup> إلى القسم ٤).</p><ul dir="rtl"><li>إذا كان جسمك يحتفظ بالماء )احتباس السوائل( أو تعاني من مشاكل فشل القلب، خاصة إذا كان عمرك فوق&nbsp;٧٥ عاما<sup>ً</sup>. إذا كنت تتناول أدوية مضادات الالتهاب التي قد تسبب أيضاَ احتباس السوائل والتورم، يجب عليك أيضا<sup>ً</sup> إخبار طبيبك بذلك.</li><li>إذا كنت تعاني من نوع خاص من أمراض العين المرتبطة بالسكري ويعرف بالوذمة البقعية (تورم العين من الخلف).</li><li>إذا كنت تعاني من تكيس المبايض (مُتَلاَزِمَة المَبيضِ المُتَعَدِّدِ الكيسات). يمكن أن تزداد إحتمالية أن تصبحي حاملاً وذلك لأنه من الممكن أن تحدث أباضة مرة أخرى عند تناول آكتوس. إذا كان هذا ينطبق عليك، قومي باستخدام وسيلة فعالة لمنع الحمل لتجنب احتمالية حدوث حمل غير مخطط له .</li><li>إذا كنت تعاني من أمراض الكبد أو القلب. سيتم أخذ عينات دم لفحص وظائف الكبد قبل البدء بتناول آكتوس. يمكن أن يتكرر هذا الفحص على فترات منتظمة. بعض مرضى السكري من النوع الثاني طويل الأمد وأمراض القلب أو الذين أصيبوا بسكتة دماغية سابقة وتم علاجهم بآكتوس مع الأنسولين قد واجهوا حدوث فشل في القلب. أبلغ طبيبك في أقرب وقت ممكن في حال واجهت أعراض لفشل القلب كضيق غير اعتيادي للنفس أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).</li><li>إذا كنت تتناول آكتوس مع أدوية أخرى لعلاج السكري، فمن المرجح أن تنخفض نسبة سكر الدم دون المستوى الطبيعي (نقص سكر الدم).</li><li>قد تصاب بنقص في تعداد الدم (فقر الدم).</li><li>كسر العظام: تم ملاحظة عدد أكبر من الكسور في العظام، خاصة عند النساء الاتي يتناولن البيوغليتازون. سيأخذ طبيبك هذا بعين الاعتبار عند معالجة السكري لديك.</li></ul><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصَ بالاستخدام لدى لأطفال والمراهقين دون سن ١٨&nbsp;عاماً.</p><p dir="RTL"><strong>أدوية أخرى وآكتوس </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا<sup>ً</sup> أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">عادةً يمكنك متابعة تناول الأدوية الأخرى خلال علاجك بآكتوس. مع ذلك، قد تؤثر بعض الأدوية على وجه الخصوص على نسبة سكر الدم:</p><ul dir="rtl"><li>جيمفيبروزيل (دواء يستخدم لخفض مستوى الكوليسترول)</li><li>ريفامبيسين (دواء يستخدم لعلاج مرض السل وأنواع أخرى من العدوى)</li></ul><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من هذه الأدوية. سيتم فحص نسبة السكر في دمك وقد تحتاج جرعة آكتوس إلى تغير.</p><p dir="RTL"><strong>آكتوس مع الطعام والشراب </strong></p><p dir="RTL">يمكنك تناول أقراصك مع أو بدون الطعام. يجب بلع الأقراص مع كوب من الماء.</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">فئة سلامة الحمل<em> </em><em>C</em></p><p dir="RTL">أخبري طبيبك إذا:</p><ul dir="rtl"><li>كنت حاملاً، تعتقدين أنك حاملاً أو تخططين لذلك.</li><li>&nbsp;كنت مرضعة أو تخططين لرضاعة طفلك.</li></ul><p dir="RTL">سوف ينصحك طبيبك بعدم استكمال هذا الدواء.</p><p dir="RTL"><strong>تأثير آكتوس على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر هذا الدواء على قيادة المركبات أو استخدام الآلات ولكن توخى الحذر إذا واجهت اضطراب في الرؤية.</p><p dir="RTL"><strong>يحتوي آكتوس على اللاكتوز</strong></p><p dir="RTL">يحتوي آكتوس على اللاكتوز. يحتوي كل قرص من آكتوس ١٥ ملغم&nbsp;و٣٠&nbsp; ملغم أقراص على ٩٢,٥٣٩&nbsp;ملغم أو ٧٦,٣٤٠ ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك أن لديك عدم تحمل لبعض أنواع السكر، تواصل مع طبيبك قبل تناول آكتوس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما<sup>ً</sup> تناول هذا الدواء تماما<sup>ً</sup> كما وصفه طبيبك أو الصيدلي لك. تحقق من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الجرعة الإبتدائية الاعتيادية هي قرص واحد من ١٥ ملغم&nbsp; أو من ٣٠ ملغم&nbsp; من البيوغليتازون مرة واحدة يوميا<sup>ً</sup>. قد يزيد لك طبيبك الجرعة إلى الحد الأعلى وهو ٤٥ ملغم&nbsp; مرة في اليوم. سيخبرك الطبيب بالجرعة التي يجب تناولها.</p><p dir="RTL">تحدث مع طبيبك، إذا كان لديك الانطباع بأن مفعول <strong>آ</strong>كتوس ضعيف.</p><p dir="RTL">سيخبرك طبيبك إذا كنت بحاجة لتناول جرعة أقل من أدويتك، إذا تم تناول آكتوس في توليفة مع أدوية أخرى تستخدم لعلاج السكري (مثل الأنسولين، الكلوربرومايد، الجليبينكلامايد، الجليكلازايد، التولبيتاميد).</p><p dir="RTL">قد يطلب طبيبك عمل فحوصات للدم بشكل دوري خلال علاجك بآكتوس. هذا للتأكد بأن الكبد يعمل بشكل طبيعي.</p><p dir="RTL">إذا كنت تتبع حمية غذائية خاصة بالسكري، يوصى بالتقيد بها أثناء تناول آكتوس.</p><p dir="RTL">يوصى بمراقبة وزنك على فترات منتظمة؛ اخبر طبيبك إذا لاحظت زيادة وزنك.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من آكتوس </strong></p><p dir="RTL">إذا تناولت جرعة زائدة من الأقراص، أو تناول شخص آخر أو إذا تناول طفل دوائك، تحدث مع طبيب أو صيدلي فورا<sup>ً</sup>. قد تنخفض نسبة سكر الدم دون الحد الطبيعي ويمكن رفعها عن طريق تناول السكر. يوصى بحمل القليل من مكعبات السكر، الحلويات، البسكويت أو عصائر الفواكه المحلاة.</p><p dir="RTL"><strong>إذا نسيت تناول آكتوس</strong></p><p dir="RTL">تناول آكتوس يوميا<sup>ً</sup> تماما<sup>ً</sup> كما تم وصفه لك. إنما إذا نسيت جرعة، تناول الجرعة التالية كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول آكتوس</strong></p><p dir="RTL">يجب تناول آكتوس يوميا<sup>ً</sup> للعمل بشكل جيد. إذا توقفت عن تناول آكتوس، قد يرتفع سكر الدم لديك. تحدث إلى طبيبك قبل التوقف عن تناول هذا العلاج.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب هذا الدواء آثارا<sup>ً</sup> جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>على وجه الخصوص، قد عانى المرضى من الآثار جانبية الخطيرة التالية</strong><strong><em>:</em></strong></p><p dir="RTL">قد عانى المرضى الذين تناولوا آكتوس في توليفة مع استخدام الأنسولين من فشل في القلب بشكل شائع (قد تؤثرعلى ما يصل إلى&nbsp;١ من كل ١٠ أشخاص). تتضمن الأعراض ضيق غير معتاد في النفس أو زيادة سريعة في الوزن أو تورم موضعي (وذمة). اطلب النصيحة الطبية فورا<sup>ً</sup> في حال حدوث أية من هذه الأعراض خاصة إذا كان عمرك فوق&nbsp;٦٥ عاما<sup>ً</sup>.</p><p dir="RTL">قد عانى المرضى الذين تناولوا آكتوس من سرطان المثانة بشكل غير شائع (قد تؤثر على ما يصل إلى ١ من كل ١٠٠ شخص) .</p><p dir="RTL">تشمل العلامات والأعراض ظهور دم في البول، ألم عند التبول أو حاجة مفاجئة للتبول. تحدث إلى طبيبك بأسرع وقت ممكن في حال حدوث أية من هذه الأعراض .</p><p dir="RTL">قد عانى المرضى الذين تناولوا آكتوس في توليفة مع استخدام الأنسولين من تورم موضعي (وذمة) بشكل شائع جدا<sup>ً</sup> (قد تؤثر على ما يصل إلى&nbsp; أكثر من ١ من كل ١٠ أشخاص). تحدث إلى طبيبك بأسرع وقت ممكن في حال حدوث أية من هذه الأعراض.</p><p dir="RTL">قد تم الإبلاغ عن كسور العظام بشكل شائع (قد تؤثرعلى ما يصل إلى&nbsp;١ من كل ١٠ أشخاص) لدى المرضى النساء اللاتي تناولن آكتوس وأيضاً تم الإبلاغ لدى المرضى الذكور الذين تناولوا آكتوس (لا يمكن تقدير التكرار من البيانات المتاحة). تحدث إلى طبيبك بأسرع وقت ممكن في حال حدوث أية من هذه الأعراض.</p><p dir="RTL">قد تم الإبلاغ أيضا<sup>ً</sup> عن تغيم في الرؤية بسبب التورم (أو سوائل) خلف العين (لا يمكن تقدير التكرار من البيانات المتاحة) لدى المرضى الذين تناولوا آكتوس. تحدث إلى طبيبك بأسرع وقت ممكن، إذا شعرت بهذا العارض للمرة الأولى. أيضا<sup>ً</sup>، تحدث إلى طبيبك بأسرع وقت ممكن في حال كنت تعاني من تغيم في الرؤية وزادت حدة هذا العارض.</p><p dir="RTL">قد تم الإبلاغ عن ردود فعل تحسسية لدى المرضى الذين تناولوا آكتوس (لا يمكن تقدير التكرار من البيانات المتاحة). إذا عانيت من رد فعل تحسسي خطير، يشمل الشرى وتورم في الوجه، الشفتين، اللسان أو الحنجرة والتي قد تسبب صعوبة في التنفس أو البلع توقف عن تناول الدواء وتحدث إلى طبيبك بأسرع وقت ممكن.</p><p dir="RTL"><em><strong>قد عانى بعض المرضى من آثار جانبية أخرى عند تناول آكتوس مثل</strong><strong>:</strong></em></p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى ١&nbsp;</strong><strong>من كل ١٠&nbsp;</strong><strong>أشخاص)</strong></p><ul dir="rtl"><li>التهاب في الجهاز التنفسي</li><li>اضطرابات الرؤية</li><li>زيادة الوزن</li><li>خدران</li></ul><p dir="RTL"><strong>غير الشائعة</strong> <strong>(قد تؤثر على ما يصل إلى ١&nbsp;</strong><strong>من كل ١٠٠&nbsp;</strong><strong>شخص)</strong></p><ul dir="rtl"><li>التهاب الجيوب الأنفية</li><li>صعوبة&nbsp; في النوم (الأرق)</li></ul><p dir="RTL"><strong>غير معروفة</strong> <strong>(لا يمكن تقدير التكرار من البيانات المتاحة)&nbsp;</strong></p><ul dir="rtl"><li>ارتفاع إنزيمات الكبد</li><li>تفاعلات تحسسية</li></ul><p dir="RTL"><em><strong>الآثار الجانبية الأخرى التي قد عانى منها بعض المرضى عند تناول آكتوس مع الأدوية الأخرى المضادة للسكري هي</strong><strong>:</strong></em></p><p dir="RTL"><strong>شائعة جداً (قد تؤثر على أكثر من ١&nbsp;</strong><strong>من كل ١٠&nbsp;</strong><strong>أشخاص)</strong></p><ul dir="rtl"><li>انخفاض في سكر الدم (نقص سكر الدم)&nbsp;</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى ١&nbsp;</strong><strong>من كل ١٠&nbsp;</strong><strong>أشخاص)</strong></p><ul dir="rtl"><li>صداع</li><li>دوخة</li><li>ألم في المفاصل</li><li>عجز جنسي</li><li>ألم الظهر</li><li>ضيق النفس</li><li>نقص قليل في عدد كريات الدم الحمراء</li><li>انتفاخ</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى ١&nbsp;</strong><strong>من كل ١٠٠&nbsp;</strong><strong>شخص)</strong></p><ul dir="rtl"><li>سكر في البول، بروتينات في البول</li><li>ارتفاع الإنزيمات</li><li>شعور بالدوار (دوخة)</li><li>تعرق</li><li>تعب</li><li>زيادة في الشهية</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ هذا الدواء بعيداً&nbsp;عن مرأى ومتناول الأطفال.</p><p>لا يحفظ عند درجة حرارة أعلى من ٣٠&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">المادة الفعالة هي هيدروكلوريد البيوغليتازون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص من آكتوس ١٥ ملغم أقراص على هيدروكلوريد البيوغليتازون يكافئ&nbsp;١٥ ملغم بيوغليتازون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص من آكتوس&nbsp;٣٠ ملغم أقراص على هيدروكلوريد البيوغليتازون يكافئ ٣٠ ملغم بيوغليتازون.</p><p dir="RTL" style="text-align:justify">المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز، كالسيوم كاربوكسي ميثيل السيلليلوز، هيدروكسي بروبيل السيلليلوز وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">آكتوس ١٥ ملغم اقراص هي أقراص دائرية محدبة لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;15&quot; على أحد الوجهين و&quot;ACTOS&quot; على الوجه الآخر في قنينات بلاستيكية من متعدد الإثيلين عالي الكثافة مغطاة بأغطية بلاستيكية مقاومة لعبث الأطفال مع مجفف جل السيليكا.</p><p dir="RTL" style="text-align:justify">آكتوس ٣٠ ملغم اقراص هي أقراص دائرية مسطحة لونها أبيض مائل إلى الأبيض المصفر، منقوش عليها &quot;30&quot; على أحد الوجهين و&quot;ACTOS&quot; على الوجه الآخر في قنينات بلاستيكية من متعدد الإثيلين عالي الكثافة مغطاة بأغطية بلاستيكية مقاومة لعبث الأطفال مع مجفف جل السيليكا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>اسم وعنوان مالك رخصة التسويق والشركة المصنعة</strong></p><p>الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p>صندوق البريد: ٤٢&nbsp;</p><p>السلط ١٩١١٠، الأردن</p><p>هاتف: ٣٤٩٢٢٠٠ (٥-٩٦٢)+</p><p>فاكس: ٣٤٩٢٢٠٣ (٥-٩٦٢)+</p><p><strong>بترخيص من:</strong></p><p>شركة تاكيدا الدوائية المحدودة</p><p>١-١ دوشوماتشي ٤-تشومي-كو</p><p>أوساكا، ٤٥٠-٨٦٤٥، اليابان</p><p>هاتف: ٢١١١-٦٢٠٤-٦-٨١+</p><p>فاكس: ٢٩٤٨-٦٢٠٤-٦-٨١+</p><p><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً )انظر التفاصيل المذكورة أدناه(. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.<br />&bull; المملكة العربية السعودية<br />المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa<br />&bull; دول الخليج العربي الأخرى<br />الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ٢٠٢/١٠؛ رقم النسخة: SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actos 30 mg Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains pioglitazone hydrochloride equivalent to 30 mg pioglitazone.

Excipient with known effect: Lactose monohydrate.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

White to off-white round flat tablets, marked with “30” on one side and “ACTOS” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:</p><p style="text-align:justify">As monotherapy</p><ul><li style="text-align:justify">In adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance</li></ul><p style="text-align:justify">As dual oral therapy in combination with</p><ul><li style="text-align:justify">Metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin</li><li style="text-align:justify">A sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.</li></ul><p style="text-align:justify">As triple oral therapy in combination with</p><ul><li style="text-align:justify">Metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.</li><li style="text-align:justify">Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).</li></ul><p style="text-align:justify">After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. The dose may be increased in increments up to 45 mg once daily.</p><p>In combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy. If patients report hypoglycaemia, the dose of insulin should be decreased.</p><p><u>Special population</u></p><p><em>Elderly</em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2). Physicians should start treatment with the lowest available dose and increase the dose gradually, particularly when pioglitazone is used in combination with insulin (see section 4.4 Fluid retention and cardiac failure).</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with impaired renal function (creatinine clearance &gt; 4 ml/min) (see section 5.2). No information is available from dialysed patients therefore pioglitazone should not be used in such patients.</p><p><em>Hepatic impairment</em></p><p>Pioglitazone should not be used in patients with hepatic impairment (see sections 4.3 and 4.4).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Actos in children and adolescents under 18 years of age have not been established. No data are available.</p><p><strong>Method of administration</strong></p><p>Pioglitazone tablets are taken orally once daily with or without food. Tablets should be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pioglitazone is contraindicated in patients with:
•Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•Cardiac failure or history of cardiac failure (NYHA stages I to IV)
•Hepatic impairment
•Diabetic ketoacidosis
•Current bladder cancer or a history of bladder cancer
•Uninvestigated macroscopic haematuria

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fluid retention and cardiac failure</strong></p><p>Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal antiinflammatory drugs, including selective COX-2 inhibitors. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.</p><p>A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years. This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.</p><p><strong>Elderly</strong></p><p>Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure.</p><p>In light of age- related risks (especially bladder cancer, fractures and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.</p><p><strong>Bladder cancer</strong></p><p>Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.</p><p>Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting pioglitazone therapy.</p><p>Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.</p><p><strong>Monitoring of liver function</strong></p><p>There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt; 2.5 X upper limit of normal) or with any other evidence of liver disease.</p><p>Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. If ALT levels remain &gt; 3 X the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.</p><p><strong>Weight gain</strong></p><p>In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. In some cases weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.</p><p><strong>Haematology</strong></p><p>There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6&ndash;4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1&ndash;2% and haematocrit 1&ndash;3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.</p><p><strong>Hypoglycaemia</strong></p><p>As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual or triple oral therapy with a sulphonylurea or in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.</p><p><strong>Eye disorders</strong></p><p>Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.</p><p><strong>Others</strong></p><p>An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.</p><p>Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).</p><p>The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.</p><p>In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).</p><p>Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women.</p><p>The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8).</p><p>As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6).</p><p>Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).</p><p>Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).</p><p>Actos tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.</p><p>Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4). Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no adequate human data to determine the safety of pioglitazone during pregnancy. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth. The relevance of such a mechanism in humans is unclear and pioglitazone should not be used in pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Pioglitazone has been shown to be present in the milk of lactating rats. It is not known whether pioglitazone is secreted in human milk. Therefore, pioglitazone should not be administered to breast-feeding women.</p><p><strong>Fertility</strong></p><p>In animal fertility studies there was no effect on copulation, impregnation or fertility index.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Actos has no or negligible influence on the ability to drive and use machines. However patients who experience visual disturbance should be cautious when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tabulated list of adverse reactions</strong></p><p>Adverse reactions reported in excess (&gt; 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to&lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="5"><p><strong>Frequency of adverse reactions of Pioglitazone by treatment regimen</strong></p></td></tr><tr><td style="width:96px"><p><strong>Monotherapy</strong></p></td><td colspan="4" style="width:369px"><p><strong>Combination</strong></p></td></tr><tr><td colspan="2" style="width:230px"><p>&nbsp;</p></td><td rowspan="2" style="width:84px"><p><strong>With metformin</strong></p></td><td rowspan="2"><p><strong>With sulphonylurea</strong></p></td><td rowspan="2"><p><strong>With metformin and sulphonylurea</strong></p></td><td rowspan="2"><p><strong>With insulin</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td style="width:96px"><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Infections &nbsp;and infestations</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Upper &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory&nbsp;&nbsp;tract infection</p></td><td style="width:96px"><p>Common</p></td><td style="width:84px"><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td><p>Bronchitis</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common</p></td></tr><tr><td><p>Sinusitis</p></td><td style="width:96px"><p>Uncommon</p></td><td style="width:84px"><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Blood and lymphatic</strong></p><p><strong>system disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Anemia</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>Common</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Immune </strong><strong>System Disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Hypersensitivity and allergic reactions<sup>1</sup></p></td><td style="width:96px"><p>Unknown</p></td><td style="width:84px"><p>Unknown</p></td><td><p>Unknown</p></td><td><p>Unknown</p></td><td><p>Unknown</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Metabolism </strong><strong>and nutrition</strong></p><p><strong>disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Hypo-glycaemia</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>Uncommon</p></td><td><p>Very common</p></td><td><p>Common</p></td></tr><tr><td><p>Appetite increased</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Hypo-aesthesia</p></td><td style="width:96px"><p>Common</p></td><td style="width:84px"><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td><p>Headache</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>Common</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dizziness</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Insomnia</p></td><td style="width:96px"><p>Uncommon</p></td><td style="width:84px"><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Eye disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Visual disturbances<sup> 2</sup></p></td><td style="width:96px"><p>Common</p></td><td style="width:84px"><p>Common</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Macular &nbsp;edema<sup>3</sup></p></td><td style="width:96px"><p>Not known frequency</p></td><td style="width:84px"><p>Not&nbsp;known</p><p>frequency</p></td><td><p>Not&nbsp;known frequency</p></td><td><p>Not&nbsp;known frequency</p></td><td><p>Not known frequency</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Ear and labyrinth disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Vertigo</p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p><strong>Cardiac disorders</strong></p></td><td colspan="5"><p>&nbsp;</p></td></tr><tr><td><p>Heart failure<sup>4</sup></p></td><td style="width:96px"><p>&nbsp;</p></td><td style="width:84px"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common</p></td></tr><tr><td colspan="6">&nbsp;</td></tr><tr><td><p><strong>Neoplasms &nbsp;benign, malignant and unspecified (including cysts and polyps)</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Bladder Cancer</p></td><td style="width:96px"><p>Uncommon</p></td><td style="width:84px"><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="6">&nbsp;</td></tr><tr><td><p><strong>Respiratory,thoracic and mediastinal disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Dyspnoea</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Common</p></td></tr><tr><td colspan="6">&nbsp;</td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Flatulence</p></td><td style="width:96px">&nbsp;</td><td style="width:84px"><p>Uncommon</p></td><td><p>Common</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td rowspan="1" colspan="5">&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Skin and subcutaneous</strong></p><p><strong>tissue disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;Sweating</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td><p>Uncommon</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td rowspan="1" colspan="5">&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Fracture bone<sup>5</sup></p></td><td style="width:96px"><p>Common</p></td><td style="width:84px"><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td><p>Arthralgia</p></td><td style="width:96px">&nbsp;</td><td style="width:84px"><p>Common</p></td><td>&nbsp;</td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td><p>Back pain</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Common</p></td></tr><tr><td rowspan="1" colspan="4">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Renal and urinary disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Haematuria</p></td><td style="width:96px">&nbsp;</td><td style="width:84px"><p>Common</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Glycosuria</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td><p>Uncommon</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Proteinuria</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td><p>Uncommon</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td rowspan="1" colspan="4">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Reproductive system and</strong></p><p><strong>breast disorders</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>erectile &nbsp;dysfunction</p></td><td style="width:96px">&nbsp;</td><td style="width:84px"><p>Common</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td rowspan="1" colspan="4">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Edema</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Very common</p></td></tr><tr><td><p>Fatigue</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td><p>Uncommon</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td rowspan="1" colspan="4">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p><strong>Investigations</strong></p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Weight increased<sup>6</sup></p></td><td style="width:96px"><p>Common</p></td><td style="width:84px"><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td><p>Blood &nbsp;&nbsp;&nbsp; creatine &nbsp;&nbsp;&nbsp;&nbsp; phospho- kinase increased</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td>&nbsp;</td><td><p>Common</p></td><td>&nbsp;</td></tr><tr><td><p>Increased&nbsp;&nbsp; &nbsp;lactic &nbsp;&nbsp;&nbsp; dehydro- genase</p></td><td style="width:96px">&nbsp;</td><td style="width:84px">&nbsp;</td><td><p>Uncommon</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Alanine &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aminotransferase increased<sup>7</sup></p></td><td style="width:96px"><p>Not&nbsp; known&nbsp;</p></td><td style="width:84px"><p>Not&nbsp; known&nbsp;</p></td><td><p>Not&nbsp; known&nbsp;</p></td><td><p>Not&nbsp; known&nbsp;</p></td><td><p>Not&nbsp;known&nbsp;</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:580px"><tbody><tr><td style="vertical-align:top"><p><u>Description of selected adverse reactions</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria.</p><p>2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.</p><p>3 In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. However, this did not lead to an increase in mortality in this study. In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged &ge;65 years compared with those less than 65 years (9.7% compared to 4.0%). In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those &ge;65 years compared to 4.0% in patients less than 65 years. Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure (see section 4.4).</p><p>4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparatortreated groups of up to 3.5 years duration. A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).</p><p>In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). Post-marketing, bone fractures have been reported in both male and female patients (see section 4.4)</p><p>5 Oedema was reported in 6&ndash;9% of patients treated with pioglitazone over one year in controlled clinical trials. The oedema rates for comparator groups (sulphonylurea, metformin) were 2&ndash;5%. The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.</p><p>6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2&ndash;3 kg over one year. This is similar to that seen in a sulphonylurea active comparator group. In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. In comparator groups addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.</p><p>7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. Mean levels of liver enzymes decreased with treatment with pioglitazone. Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. Although in very rare cases fatal outcome has been reported, causal relationship has not been established.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext: 2317-2356-2340.</p><p>Reporting hotline: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&bull;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.</p><p>Hypoglycaemia may occur in combination with sulphonylureas or insulin. Symptomatic and general supportive measures should be taken in case of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03.</p><p>Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.</p><p>Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA<sub>1c</sub>&ge; 8.0% after the first six months of therapy). Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone. At two years, glycaemic control (defined as HbA<sub>1c </sub>&lt; 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA<sub>1c </sub>was similar between treatment groups after one year. The rate of deterioration of HbA<sub>1c </sub>during the second year was less with pioglitazone than with gliclazide.</p><p>In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. Patients receiving pioglitazone had a mean reduction in HbA<sub>1c </sub>of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.</p><p>HOMA analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity. Two-year clinical studies have shown maintenance of this effect.</p><p>In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.</p><p>The effect of pioglitazone (45 mg monotherapy <em>vs. </em>placebo) was studied in a small 18-week trial in type 2 diabetics. Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.</p><p>In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL cholesterol levels, compared with placebo, metformin or gliclazide. Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. In a 20week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone&#39;s effects on glycaemia and were statistically significantly different to glibenclamide.</p><p>In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. The study population had an average age of 62 years; the average duration of diabetes was 9.5 years. Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea. To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke. Approximately half of the study population had at least two of the cardiovascular history entry criteria. Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, acetylsalicylic acid, statins, fibrates).</p><p>Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. However, the incidences of oedema, weight gain and heart failure were increased. No increase in mortality from heart failure was observed.</p><p><strong>Paediatric population</strong></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Actos in all subsets of the paediatric population in type 2 diabetes mellitus. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the plasma concentration were observed for doses from 2&ndash;60 mg. Steady state is achieved after 4&ndash;7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.</p><p><strong>Distribution</strong></p><p>The estimated volume of distribution in humans is 0.25 L/kg.</p><p>Pioglitazone and all active metabolites are extensively bound to plasma protein (&gt; 99%).</p><p><strong>Biotransformation</strong></p><p>Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified metabolites are active (M-II, M-III, and MIV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.</p><p><em>In vitro </em>studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man.</p><p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).</p><p><strong>Elimination</strong></p><p>Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. The mean plasma elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.</p><p><strong>Elderly</strong></p><p>Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.</p><p><strong>Patients with renal impairment</strong></p><p>In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus free (unbound) pioglitazone concentration is unchanged.</p><p><strong>Patients with hepatic impairment</strong></p><p>Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. In addition, increased fatty deposition and infiltration were observed. These findings were observed across species at plasma concentrations &le; 4 times the clinical exposure. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.</p><p>Pioglitazone was devoid of genotoxic potential in a comprehensive battery of <em>in vivo </em>and <em>in vitro </em>genotoxicity assays. An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.</p><p>The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. Dietary acidification significantly decreased but did not abolish the incidence of tumours. The presence of microcrystals exacerbated the hyperplastic response but was not considered to be the primary cause of hyperplastic changes. The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.</p><p>There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.</p><p>In an animal model of familial adenomatous polyposis (FAP), treatment with two other thiazolidinediones increased tumour multiplicity in the colon. The relevance of this finding is unknown.</p><p><strong>Environmental Risk Assessment (ERA):</strong></p><p>No environmental impact is anticipated from the clinical use of pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-Carmellose calcium</p><p>- Hydroxylpropycellulose</p><p>- Lactose monohydrate</p><p>-&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Plastic Caps for 30 ml HDPE bottle with silica gel.</p><p>Pack size: 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Arab Pharmaceutical Manufacturing PSC
P.O. Box 42
Sult, Jordan
Tel: + (962-5)3492200
Fax: + (962-5)3492203

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 October 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>